Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.
Latest From Andrew McConaghie
The GSK-led joint venture has taken the lead in long-acting HIV treatment and prevention but has put back timelines on a key self-administered candidate.
CD47 was once seen as one of the hottest properties in immunotherapy, but multiple setbacks have tempered enthusiasm for targeting the ‘don’t eat me’ cell surface protein. I-Mab and Gilead are just two casualties.
The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.
The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.
Promising Early Results For AZ And Daiichi’s Dato-DXd In Breast Cancer – But How Soon Can They File?
Once again choosing their words carefully, the partners talk only of ‘plans’ to file as regulators will first have to clarify when overall survival data will be required for the new antibody-drug conjugate in breast cancer.
Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.